daraxonrasib

also known as RMC-6236

Small molecule targets HRAS, KRAS, NRAS via inhibition

Developed for: pancreatic ductal adenocarcinoma · non-small cell lung carcinoma · colorectal cancer · pancreatic adenosquamous carcinoma · cancer · metastatic neoplasm · lung cancer
Investigated by: Revolution Medicines, Inc. · Bristol-Myers Squibb · Summit Therapeutics · Tango Therapeutics, Inc.

Trials 14 · a red edge is where a trial was stopped

today NCT07492680 · Ph 2 NCT07491445 · Ph 3 NCT07397338 · Ph 1/2 NCT07349537 · Ph 1 NCT07252232 · Ph 3 NCT06922591 · Ph 1/2 NCT06881784 · Ph 3 NCT06625320 · Ph 3 NCT06445062 · Ph 1/2 NCT06162221 · Ph 1/2 NCT06128551 · Ph 1/2 NCT06040541 · Ph 1 NCT05379985 · Ph 1/2

2023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 12 trials
Phase 1	NCT07349537	Jan 2026 → Apr 2028 expected	colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma	Revolution Medicines, Inc.	Recruiting	No outcome recorded
Phase 1	NCT06040541	Sep 2023 → Dec 2026 expected	colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma	Revolution Medicines, Inc.	Recruiting	No outcome recorded
Phase 1/26 trials
Phase 1/2	NCT07397338	Jan 2026 → May 2029 expected	colorectal cancer, metastatic neoplasm, non-small cell lung carcinoma	Revolution Medicines, Inc.	Recruiting	No outcome recorded
Phase 1/2	NCT06922591	May 2025 → Jun 2027 expected	non-small cell lung carcinoma, pancreatic ductal adenocarcinoma	Tango Therapeutics, Inc.	Recruiting	No outcome recorded
Phase 1/2	NCT06445062	May 2024 → May 2027 expected	colorectal cancer, pancreatic ductal adenocarcinoma	Revolution Medicines, Inc.	Recruiting	No outcome recorded
Phase 1/2	NCT06162221	Jan 2024 → Jun 2027 expected	non-small cell lung carcinoma	Revolution Medicines, Inc.	Recruiting	No outcome recorded
Phase 1/2	NCT06128551	Nov 2023 → Dec 2028 expected	colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma	Revolution Medicines, Inc.	Recruiting	No outcome recorded
Phase 1/2	NCT05379985	May 2022 → May 2027 expected	colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma	Revolution Medicines, Inc.	Recruiting	No outcome recorded
Phase 21 trial
Phase 2	NCT07492680	Jul 2026 → Aug 2028 expected	cancer	Bristol-Myers Squibb	Not yet recruiting	No outcome recorded
Phase 34 trials
Phase 3	NCT07491445	Mar 2026 → Jun 2028 expected	pancreatic adenosquamous carcinoma, pancreatic ductal adenocarcinoma	Revolution Medicines, Inc.	Recruiting	No outcome recorded
Phase 3	NCT07252232	Dec 2025 → May 2029 expected	pancreatic ductal adenocarcinoma	Revolution Medicines, Inc.	Recruiting	No outcome recorded
Phase 3	NCT06881784	May 2025 → Dec 2027 expected	non-small cell lung carcinoma	Revolution Medicines, Inc.	Recruiting	No outcome recorded
Phase 3	NCT06625320	Oct 2024 → Jun 2026 overdue	pancreatic ductal adenocarcinoma	Revolution Medicines, Inc.	Active not recruiting	No outcome recorded
Phase not stated1 trial
—	NCT07573215	—	pancreatic adenosquamous carcinoma, pancreatic ductal adenocarcinoma	Revolution Medicines, Inc.	Available	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT06360354 Background	May 2024 → Oct 2026 expected	digestive system carcinoma	Amgen	Active not recruiting	No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 17 sources stand behind the page.

Field	Value	Cited text
Known as	daraxonrasib	“Herein, we describe the structure-guided SAR journey that led to the discovery of daraxonrasib (RMC-6236), a noncovalent, potent tri-complex inhibitor of multiple RAS mutant...” PMID 40056080 ↗ Mar 2025 9 “Daraxonrasib (RMC-6236) is an oral RAS(ON) multiselective inhibitor that targets guanosine triphosphate-bound mutant and wild-type RAS.” PMID 42090791 ↗ May 2026 NCT07252232 ↗ NCT07397338 ↗ NCT06128551 ↗ NCT07492680 ↗ NCT07491445 ↗ NCT07573215 ↗ NCT06881784 ↗ NCT07349537 ↗
Known as	RMC-6236	“Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)” NCT07252232 ↗ 8 “Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)” NCT06881784 ↗ NCT06162221 ↗ NCT06040541 ↗ NCT06625320 ↗ NCT06445062 ↗ NCT05379985 ↗ NCT06360354 ↗ NCT06922591 ↗
Action	Inhibit	“RMC-6236 is a potent, orally bioavailable RAS-MULTI(ON) inhibitor, selective for the active RAS(ON) form of both wild type and mutant variants of the canonical RAS isoforms...” NCT05379985 ↗
Modality	Small molecule	“This orally bioavailable bRo5 macrocyclic molecule occupies a unique composite binding pocket comprising CypA and SWI/SWII regions of RAS(ON).” PMID 40056080 ↗ Mar 2025
Route	Oral	“Patients received 10 to 400 mg of daraxonrasib orally once daily” PMID 42090791 ↗ May 2026
Target	HRAS	“RMC-6236 is a potent, orally bioavailable RAS-MULTI(ON) inhibitor, selective for the active RAS(ON) form of both wild type and mutant variants of the canonical RAS isoforms...” NCT05379985 ↗
Target	KRAS	“RMC-6236 is a potent, orally bioavailable RAS-MULTI(ON) inhibitor, selective for the active RAS(ON) form of both wild type and mutant variants of the canonical RAS isoforms...” NCT05379985 ↗
Target	NRAS	“RMC-6236 is a potent, orally bioavailable RAS-MULTI(ON) inhibitor, selective for the active RAS(ON) form of both wild type and mutant variants of the canonical RAS isoforms...” NCT05379985 ↗